KCNA5 encodes Kv1.5, a voltage-gated potassium channel alpha subunit that contributes to delayed rectifier currents and controls action-potential repolarization in excitable tissues.[1][2] The strongest clinical signal for KCNA5 is in atrial electrophysiology, but the channel is also present in brain and vascular compartments where it shapes neuronal firing, neurovascular coupling, and stress-response excitability.[1:1][3]
For neurodegenerative medicine, KCNA5 is not currently a major causal gene like SNCA or MAPT. Its importance is systems-level and translational: it sits at the interface of neuronal excitability, vascular function, and metabolic demand, all of which influence disease progression and symptom burden.[2:1][4]
| Property | Value |
|---|---|
| HGNC symbol | KCNA5 |
| Encoded channel | Kv1.5 |
| NCBI Gene | 3746 |
| Genomic locus | 12p13.31 |
| Protein class | Shaker-related voltage-gated potassium channel |
Kv1.5 has six transmembrane segments (S1-S6), a voltage-sensing S4 helix, and a pore-forming loop between S5-S6. Channel opening during depolarization promotes repolarization and limits repetitive firing.[1:2][2:2]
Kv1.5 contributes to spike waveform control and refractory behavior in subsets of neurons and glia-associated signaling environments.[1:3][2:3] Changes in Kv1.5 availability can influence burst propensity and synaptic release dynamics, affecting cognitive and motor network stability.
Although much of the literature is cardiac, KCNA5-regulated currents in vascular beds influence smooth muscle tone and perfusion responsiveness.[3:1][4:1] Neurodegenerative diseases with vascular comorbidity may therefore be sensitive to Kv1.5-dependent perfusion constraints.
Kv1.5 function is dynamically altered by phosphorylation, trafficking, oxidation state, and inflammatory signaling.[4:2][5] These are the same stress axes active in Parkinson's disease, Alzheimer's disease, and mixed vascular-neurodegenerative syndromes.
Loss- or gain-of-function KCNA5 variants have been linked to atrial fibrillation and conduction phenotypes.[3:2] This confirms functional sensitivity of the locus and supports precision electrophysiology approaches.
Evidence for direct neurodegeneration causality remains limited. The strongest rationale is mechanistic convergence:
This places KCNA5 in a candidate-modifier tier for disease progression and symptom heterogeneity rather than primary diagnosis.
Kv1.5 is pharmacologically tractable and heavily studied in cardio-electrophysiology, offering a translational scaffold for CNS-adjacent applications.[1:4][3:3] Potential neuro applications include:
Key caution: because Kv1.5 modulation can affect cardiac rhythm, CNS-directed programs must include rigorous off-target cardiac monitoring.
| Dimension | Appraisal |
|---|---|
| Channel biophysics | Strong |
| Human cardiac genetics/clinical evidence | Strong |
| Direct neurodegeneration causality | Limited |
| Translational actionability | Moderate |
Fedida D, Wible B, Wang Z, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circulation Research. 1993. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Coetzee WA, Amarillo Y, Chiu J, et al. Molecular diversity of K+ channels. Annual Review of Physiology. 1999. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Christophersen IE, Olesen MS, Liang B, et al. Genetic variation in KCNA5 and atrial fibrillation susceptibility. Heart Rhythm. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Tamargo J, Caballero R, Delpón E. Pharmacology of cardiac potassium channels. Cardiovascular Research. 2004. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Svoboda LK, Reddie KG, Zhang L, et al. Oxidative and signaling-dependent regulation of Kv1.5 channel trafficking. Proceedings of the National Academy of Sciences. 2021. ↩︎ ↩︎